Source: Google NewsPublished on 2021-01-05
Related Articles:
- ALS: From ice bucket to centaur November 18, 2020 # # # # Amyotrophic lateral sclerosis (or ALS) is the third most common neurodegenerative condition. It is characterised by the loss of motor neurons, which leads to loss of muscle control. As with Parkinson’s, there is no cure for ALS, and there are only two FDA approved therapies for the condition. Recently, a biotech company – called Amylyx Pharmaceuticals…
- Spinogenix Announces Grant by US Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) - BioSpace January 5, 2021 Spinogenix Announces Grant by US Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) BioSpace
- The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
- Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) - Yahoo Finance January 5, 2021 Spinogenix Announces Grant by U.S. Department of Defense to Advance Novel Drug Candidate in Amyotrophic Lateral Sclerosis (ALS) Yahoo Finance
- Monthly Research Review – November 2020 November 30, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- High BMI, Weight Gain Associated With Low ALS Risk Decades Later July 30, 2019 High pre-diagnostic body mass index (BMI) and weight gain are associated with a lower risk for amyotrophic lateral sclerosis (ALS) several decades later, according to a study published in Neurology. In this population-based study, researchers collected objectively measured BMI from 85% of citizens aged 20 to 70 years who and living in 18 out of 19 Norwegian counties between 1963…
- Significant Motor Cortex Degeneration in ALS According to MRS Findings July 17, 2019 In amyotrophic lateral sclerosis (ALS), cerebral degeneration is typically more pronounced in the motor cortex compared with the prefrontal cortex, according to research published in Neurology: Clinical Practice. Researchers used single-voxel, proton, magnetic resonance spectroscopy (MRS) to examine cerebral degeneration and neurochemistry in patients with ALS. Participants included 65 individuals with ALS, and 43 age matched healthy controls recruited form…
- Monthy research review – December 2019 December 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population. March 18, 2019 Related ArticlesERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population. Neurol Sci. 2019 Mar 16;: Authors: Dardiotis E, Karampinis E, Siokas V, Aloizou AM, Rikos D, Ralli S, Papadimitriou D, Bogdanos DP, Hadjigeorgiou GM Abstract BACKGROUND: Α number of genetic variants have been associated with amyotrophic lateral sclerosis (ALS). A recent study supports that rs591486 across the…
- Novel Treatment for ALS Gains Orphan Drug Status August 19, 2019 The Food and Drug Administration (FDA) has granted Orphan Drug designation to an investigational therapy for the treatment of amyotrophic lateral sclerosis (ALS). NPT520-34 (Neuropore Therapies) is an orally bioavailable, blood-brain barrier penetrating small molecule which has been shown to reduce markers of brain neuroinflammation by decreasing neurotoxic misfolded proteins (superoxide dismutase 1) in animal models. Related ArticlesSignificant Motor Cortex…
- Monthly Research Review – December 2020 December 31, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
- Monthly research review: February 2020 February 29, 2020 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
- Monthly Research Review – November 2019 November 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Peripheral Immune Biomarkers and Neurodegenerative Diseases: A Prospective Cohort Study with 20 Years of Follow-up. October 12, 2019 Peripheral Immune Biomarkers and Neurodegenerative Diseases: A Prospective Cohort Study with 20 Years of Follow-up. Ann Neurol. 2019 Oct 11;: Authors: Yazdani S, Mariosa D, Hammar N, Andersson J, Ingre C, Walldius G, Fang F Abstract OBJECTIVE: To assess the associations of several blood immune biomarkers with the future risks of amyotrophic lateral sclerosis and Parkinson disease in a prospective cohort…
- APDA ANNOUNCES $1.7 MILLION IN NEW PARKINSON’S DISEASE RESEARCH GRANTS. FUNDING ENABLES 10 RESEARCHERS TO CONDUCT IMPACTFUL RESEARCH. September 10, 2019 APDA announces funding for 2019-2020 grants It is that time of year – when APDA announces our research grantees for the 2019-2020 fiscal year. We are very proud of our grant recipients who each has a unique idea that will hopefully benefit the entire Parkinson’s disease (PD) community. This year APDA has awarded $1.7 million in grants that will support…
- APB-102 Receives Orphan Drug Designation for Genetic SOD1 ALS July 25, 2019 The Food and Drug Administration (FDA) has granted Orphan Drug designation to APB-102 (Apic Bio, Inc.) for the treatment of genetic superoxide dismutase 1 (SOD1) enzyme amyotrophic lateral sclerosis (ALS). SOD1 ALS is caused by mutations in the gene that produces the copper zinc SOD1 enzyme, which leads to the degeneration of motor neurons and muscle control typically seen in…
- People with White Collar Jobs More Likely to Die from ALS or Parkinson’s, CDC Study Finds July 19, 2017 A Centers for Disease Control and Prevention (CDC) study of more than 12 million people who died in the U.S. between 1985 and 2011 found that deaths from Parkinson’s disease and ALS (amyotrophic lateral sclerosis) occurred more often in people in higher socioeconomic status (SES) occupations. Findings from the study were reported in the article, “Mortality from Amyotrophic Lateral Sclerosis…
- Drug S-oxidation and phenylalanine hydroxylase: a biomarker for neurodegenerative susceptibility in Parkinson's disease and amyotrophic lateral sclerosis. April 3, 2019 Related ArticlesDrug S-oxidation and phenylalanine hydroxylase: a biomarker for neurodegenerative susceptibility in Parkinson's disease and amyotrophic lateral sclerosis. Drug Metab Pers Ther. 2019 Apr 02;: Authors: Rawlings L, Turton L, Mitchell SC, Steventon GB Abstract Background The S-oxidation of S-carboxymethyl-L-cysteine has been reported previously to be a biomarker of disease susceptibility in Parkinson's disease and amyotrophic lateral sclerosis. In the…
- Monthly Research Review – August 2019 August 31, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during August 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- Monthly Research Review – September 2019 September 30, 2019 At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
- There’s gold in them tha brains November 10, 2019 It feels as though novel potential therapies for Parkinson’s are being proposed with an ever increasing frequency. And just when I think there must be few other ways of attacking the condition, a new method is proposed. Recently a biotech firm called Clene Nanomedicine presented data on one such new approach. The experimental treatment is called CNM-Au8 and it…